Leadership Transition Recent leadership change with a former CEO moving to a Parkinson's cell therapy startup signals potential strategic shifts and openness to partnerships or advisory collaborations to align on Neurological disorder pipelines.

Workforce Rationalization Significant headcount reductions and restructuring in 2024 indicate cost containment and potential vendor/outsourcing opportunities, as well as a focus on core programs, creating room for service providers to support remaining operations.

Asset Divestitures Sale of assets to Merz Group suggests a strategic re-prioritization; opportunities may exist to offer post-transaction services, licensing partnerships, or collaboration on remaining therapies and development efforts.

Product Focus Commercial medicines for MS and Parkinson’s imply demand in neurology markets; potential for partnerships around distribution, patient access programs, or adjunct therapies leveraging Acorda’s existing portfolio and sales channels.

Global Expansion Regulatory submissions for INBRIJA in six Latin American countries highlight international growth momentum; explore regional market access, local manufacturing, and repackaging/dispensing partnerships to accelerate penetration.